Bristol Myers Squibb (CELG-RI) Land & Improvements (2025 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Land & Improvements of $157.0 million for Q1 2026, little changed sequentially from $157.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Land & Improvements (2025 - 2026) Analysis & Trends
Bristol Myers Squibb has disclosed Land & Improvements across 2 years of filings, most recently posting $157.0 million for Q1 2026.
- In Q1 2026, Land & Improvements changed N/A year-over-year to $157.0 million; the TTM figure through Mar 2026 stood at $157.0 million (changed N/A YoY), while the FY2025 annual figure was $157.0 million, changed N/A from the prior year.
- Land & Improvements steadied at $157.0 million in Q1 2026, from $157.0 million in the prior quarter.
- Over the last five years, Land & Improvements for CELG-RI reached as high as $157.0 million in Q4 2025 and fell as low as $157.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Land & Improvements (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | 157.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157.00 Mn |
| Dec 31, 2025 | 157.00 Mn |